Share Buyback
EKF Diagnostics Holdings plc has purchased 80,000 of its ordinary shares at a weighted average price of 24.85 pence per share, with the highest price paid being 25.00 pence and the lowest 24.80 pence. These shares will be cancelled, reducing the total issued share capital to 428,448,112 ordinary shares, all of which carry voting rights.
Select text to share a quote on X · sign in to keep highlights & notes in your EKF notes
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that it has purchased a total of 80,000 of its ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a weighted average price of 24.85p pence per share. The purchased shares will be cancelled.
Aggregated information
| Date of purchase | 20 August 2026 | ||
|---|---|---|---|
| Number of Ordinary Shares purchased | 80,000 | ||
| Highest price paid per Ordinary Share | 25.00 p | ||
| Lowest price paid per Ordinary Share | 24.80 p | ||
| Volume weighted average price paid | 24.85 p | ||
| Transaction details | |||
| Number of Ordinary Shares purchased | Transaction price (GBp) | Time of transaction | Trading venue |
| 40,000 | 24.8 p | 12:41:50 | AIMX |
| 20,000 | 24.8p | 16:23:24 | AIMX |
| 20,000 | 25.0p | 16:44:01 | AIMX |
Total voting rights
Following the purchase and after the cancellation of the shares becomes effective, the Company's total issued share capital will consist of 428,448,112 Ordinary Shares. There are no shares held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 428,448,112. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The person responsible for arranging the release of this Announcement
on behalf of the Company is Julian Baines, Executive Chair.
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com |
| Julian Baines, Executive Chair | via Walbrook PR |
| Gavin Jones, Chief Executive Officer | |
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 |
| Jen Boorer / Russell Cook / Patrick Weaver | |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.